Dashboard
Manage Tickers

KYMR Kymera Therapeutics, Inc.

Nasdaq kymeratx.com


$ 59.01 $ 0.00 (0 %)    

Wednesday, 05-Nov-2025 05:51:56 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 617.74 $ 0.00 (0 %)
DIA $ 470.99 $ 0.00 (0 %)
SPY $ 674.32 $ 0.00 (0 %)
TLT $ 90.00 $ 0.00 (0 %)
GLD $ 364.87 $ 0.00 (0 %)
$ 59.91
$ 55.80
$ 55.96 x 70
$ 63.50 x 2
-- - --
$ 19.45 - $ 63.96
830,778
na
4.31B
$ 2.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-11-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

10-analysts-have-this-to-say-about-kymera-therapeutics
10 Analysts Have This To Say About Kymera ...
11/05/2025 11:45:40

hc-wainwright--co-maintains-buy-on-kymera-therapeutics-raises-price-target-to-84
HC Wainwright & Co. Maintains Buy on Kymer...
11/05/2025 11:42:19

HC Wainwright & Co. analyst Andrew S. Fein maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

update-kymera-therapeutics-q3-adj-eps-090-misses-081-estimate-sales-2764m-miss-18852m-estimate
UPDATE: Kymera Therapeutics Q3 Adj. EPS $(...
11/04/2025 14:40:01

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of...

kymera-therapeutics-q3-eps-094-misses-083-estimate-sales-2764m-miss-18852m-estimate
Kymera Therapeutics Q3 EPS $(0.94) Misses ...
11/04/2025 12:02:55

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

guggenheim-assumes-kymera-therapeutics-at-buy-announces-price-target-of-90
Guggenheim Assumes Kymera Therapeutics at ...
11/03/2025 13:14:41

Guggenheim analyst Brad Canino assumes Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and announces Price Target of $90.

kymera-therapeutics-presents-new-preclinical-data-for-kt-579-oral-irf5-degrader-demonstrating-disease-modifying-activity-across-multiple-immuno-inflammatory-diseases-at-acr-2025
Kymera Therapeutics Presents New Preclinic...
10/27/2025 11:12:09

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and...

btig-maintains-buy-on-kymera-therapeutics-raises-price-target-to-75
BTIG Maintains Buy on Kymera Therapeutics,...
10/22/2025 11:34:23

BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $59 to ...

mizuho-initiates-coverage-on-kymera-therapeutics-with-outperform-rating-announces-price-target-of-81
Mizuho Initiates Coverage On Kymera Therap...
10/21/2025 12:38:26

Mizuho analyst Joseph Catanzaro initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announc...

the-analyst-verdict-kymera-therapeutics-in-the-eyes-of-6-experts
The Analyst Verdict: Kymera Therapeutics I...
10/17/2025 18:01:08

citigroup-maintains-buy-on-kymera-therapeutics-raises-price-target-to-80
Citigroup Maintains Buy on Kymera Therapeu...
10/17/2025 15:24:56

Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $60 ...

oppenheimer-maintains-outperform-on-kymera-therapeutics-raises-price-target-to-63
Oppenheimer Maintains Outperform on Kymera...
10/01/2025 13:37:12

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target fro...

truist-securities-maintains-buy-on-kymera-therapeutics-raises-price-target-to-68
Truist Securities Maintains Buy on Kymera ...
09/30/2025 14:32:05

Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

hc-wainwright--co-maintains-buy-on-kymera-therapeutics-raises-price-target-to-70
HC Wainwright & Co. Maintains Buy on Kymer...
09/18/2025 13:52:32

HC Wainwright & Co. analyst Andrew S. Fein maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

kymera-advances-oral-stat6-degrader-toward-phase-2b-trials-in-atopic-dermatitis-and-asthma-after-positive-early-data-set-for-late-breaking-presentations-at-major-european-medical-conferences
Kymera Advances Oral STAT6 Degrader Toward...
09/17/2025 11:09:08

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecul...

barclays-initiates-coverage-on-kymera-therapeutics-with-overweight-rating-announces-price-target-of-60
Barclays Initiates Coverage On Kymera Ther...
09/17/2025 10:53:30

Barclays analyst Etzer Darout initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Overweight rating and announces...

breaking-down-kymera-therapeutics-4-analysts-share-their-views
Breaking Down Kymera Therapeutics: 4 Analy...
09/16/2025 21:01:18

this-chubb-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday
This Chubb Analyst Begins Coverage On A Bu...
09/16/2025 13:22:50

rbc-capital-initiates-coverage-on-kymera-therapeutics-with-outperform-rating-announces-price-target-of-70
RBC Capital Initiates Coverage On Kymera T...
09/16/2025 13:02:19

RBC Capital analyst Brian Abrahams initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and anno...

kymera-therapeutics-q2-eps-095-misses-084-estimate-sales-11476m-miss-21214m-estimate
Kymera Therapeutics Q2 EPS $(0.95) Misses ...
08/11/2025 11:04:34

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION